University of Notre Dame DU Lac lessened its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 71.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 72,188 shares of the biotechnology company’s stock after selling 177,743 shares during the quarter. University of Notre Dame DU Lac owned about 0.16% of Atara Biotherapeutics worth $2,985,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board increased its holdings in Atara Biotherapeutics by 53.9% in the 2nd quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock valued at $1,521,000 after purchasing an additional 14,500 shares during the last quarter. Rhumbline Advisers increased its holdings in Atara Biotherapeutics by 16.9% in the 2nd quarter. Rhumbline Advisers now owns 39,238 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 5,673 shares during the last quarter. United Services Automobile Association increased its holdings in Atara Biotherapeutics by 28.4% in the 2nd quarter. United Services Automobile Association now owns 8,132 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 1,797 shares during the last quarter. Highland Private Wealth Management acquired a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $202,000. Finally, JPMorgan Chase & Co. increased its holdings in Atara Biotherapeutics by 35.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock valued at $49,741,000 after purchasing an additional 315,921 shares during the last quarter.
Shares of NASDAQ:ATRA traded up $1.13 during trading on Tuesday, hitting $43.59. The company’s stock had a trading volume of 1,745 shares, compared to its average volume of 553,316. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -10.90 and a beta of 2.61. Atara Biotherapeutics Inc has a fifty-two week low of $13.20 and a fifty-two week high of $54.45.
Several equities analysts have commented on ATRA shares. BidaskClub downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 10th. Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 9th. Finally, Cowen restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $47.80.
In related news, insider Joe Newell sold 1,500 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $41.14, for a total transaction of $61,710.00. Following the completion of the transaction, the insider now owns 33,358 shares in the company, valued at $1,372,348.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the business’s stock in a transaction on Monday, October 22nd. The stock was sold at an average price of $33.78, for a total transaction of $131,742.00. Following the transaction, the chief executive officer now owns 733,285 shares of the company’s stock, valued at approximately $24,770,367.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 97,149 shares of company stock valued at $3,755,783. Insiders own 10.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/12/04/university-of-notre-dame-du-lac-has-2-99-million-stake-in-atara-biotherapeutics-inc-atra.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Article: What does earnings per share mean?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.